Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-12-26
2006-12-26
Lambkin, Deborah C. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C548S429000, C548S430000
Reexamination Certificate
active
07153882
ABSTRACT:
The present invention provides compounds and methods of administering compounds to a subject that can reduce βAPP production and that is not toxic in a wide range of dosages. The present invention also provides non-carbamate compounds and methods of administering such compounds to a subject that can reduce βAPP production and that is not tocix in a wide range of dosages. It has been discovered that either the racemic or enantiomerically pure non-carbamate compounds can be used to decrease βAPP production.
REFERENCES:
patent: 2890223 (1959-06-01), Wolly et al.
patent: 4791107 (1988-12-01), Hamer et al.
patent: 4900748 (1990-02-01), Brossi et al.
patent: 5171750 (1992-12-01), Brossi et al.
patent: 5378723 (1995-01-01), Brossi et al.
patent: 5403851 (1995-04-01), D'Orlando et al.
patent: 5726323 (1998-03-01), Glamkowski et al.
patent: 6410747 (2002-06-01), Greig et al.
patent: 6683105 (2004-01-01), Greig et al.
patent: 6706750 (2004-03-01), Bentley et al.
patent: 2001/0007877 (2001-07-01), Burton et al.
patent: 2002/0004198 (2002-01-01), Hardwicke
patent: 0506532 (1992-09-01), None
patent: 7-271066 (1995-10-01), None
patent: WO 95/01334 (1995-01-01), None
patent: WO 96/03377 (1996-02-01), None
patent: WO 99/02154 (1999-01-01), None
patent: WO 99/43654 (1999-09-01), None
patent: WO 01/34146 (2001-05-01), None
patent: WO 01/78721 (2001-10-01), None
Adem et al., “Muscarinic receptors in human SH-SY5Y neuroblastoma cell line: regulation by phorbol ester and retinoic acid-induced differentiation.”Dev. Brain Res. 33:235-242 (1987).
Akiyama et al., “Inflammation and Alzheimer's disease.”Neurobiol. Aging. 21:383-421 (2000).
Becker et al., “The second generation of cholinesterase inhibitors: clinical and pharmacological effects.”The Cholinergic Basis for Alzheimer Therapy. Becker et al., eds. Birkhauser, Boston, 263-296 (1991).
Bhasker et al., “The Putative Iron-Responsive Element in the Human Erythroid 5-Aminolevulinate Synthase mRNA Mediates Translational Control.”J. Biol. Chem. 268(17):12699-12705 (Jun. 15, 1993).
Borchelt et al., “Accelerated Amyloid Deposition in the Brains of Transgenic Mice Coexpressing Mutant Presenilin 1 and Amyloid Precursor Proteins.”Neuron. 19(4):939-945 (Oct. 1997).
Breitner, “Inflammatory Processes and Antiinflammatory Drugs in Alzheimer's Disease: A Current Appraisal.”Neurobiol. Aging. 17(5):789-794 (1996).
Bronfman et al., “Amyloid Precursor Protein Fragment and Acetylcholinesterase Increase with Cell Confluence and Differentiation in a Neuronal Cell Line.”Exp. Cell Res. 229:93-99 (1996).
Brossi et al., “Phenserine, a Novel Anticholinesterase Related to Physostigmine: Total Synthesis, and Biological Properties.”Austr. J. Chem. 49:171-181 (1996).
Buxbaum et al., “Processing of Alzheimer β/A4 amyloid precursor protein: Modulation by agents that regulate protein phosphorylation.”Proc. Natl. Acad. Sci. USA87(15):6003-6006 (Aug. 1990).
Buxbaum et al., “Calcium regulates processing of the Alzheimer amyloid protein precursor in a protein kinase C-independent manner.”Proc. Natl. Acad. Sci. USA91:4489-4493 (May 1994).
Buxbaum et al., “Cholinergic agonists and interleukin 1 regulate processing and secretion of the Alzheimer β/A4 amyloid protein precursor.”Proc. Natl. Acad. Sci. USA89:10075-10078 (Nov. 1992).
Caputi et al., “Increase Secretion of the Amino-Terminal Fragment of Amyloid Precursor Protein in Brains of Rats with a Constitutive Up-Regulation of Protein Kinase C.”J. Neurochem. 68(6):2523-2529 (1997).
Checler, “Processing of β-Amyloid Precursor Protein and Its Regulation in Alzheimer's Disease.”J. Neurochem. 65(4):1431-1444 (1995).
Desdouits et al., “Amyloid β Peptide Formation in Cell-Free Preparations: Regulation by protein kinase C, calmodulin and calcineurin.”J. Biol. Chem. 271(40):24670-24674 (Oct. 4, 1996).
Desdouits-Magnen et al., “Regulation of Secretion of Alzheimer Amyloid Precursor Protein by the Mitogen-Activated Protein Kinase Cascade.”J. Neurochem. 70(2):524-530 (1998).
Dyrks et al., “Amyloid precursor protein secretion and βA4 amyloid generation are not mutually exclusive.”FEBS Lett. 349:210-214 (1994).
Eisenstein et al., “Iron-responsive Element-binding Protein: phosphorylation by protein kinase C.”J. Biol. Chem. 268(36):27363-27370 (Dec. 25, 1993).
Felder et al., “Muscarinic Acetylcholine Receptor Subtypes Associated with Release of Alzheimer Amyloid Precursor Derivatives Activate Multiple Signal Transduction Pathways.”Ann. NY Acad. Sci. 695:15-18 (1993).
Funato et al., “Astrocytes Containing Amyloid β-Protein (A β)-Positive Granules Are Associated with Aβ40-Positive Diffuse Plaques in the Aged Human Brain.”Am. J. Path. 152(4):983-992 (Apr. 1998).
Giaconbini et al., “The Effect of Cholinesterase Inhibitiors on the Secretion of APPS from Rat Brain Cortex.”Ann. NY Acad. Sci. 777:393-398 (1996).
Greig et al., “Phenserine and Ring-C Hetero-Analogues: Drug Candidates for the Treatment of Alzheimer's Disease.”Med. Chem. Rev. 15(1):3-31 (1995).
Haroutunian et al., “Pharmacological modulation of Alzheimer's β-amyloid precursor protein levels in the CSF of rats with forebrain cholinergic system lesions.”Mol. Brain Res. 46(1-2):161-168 (1997).
He et al., “Thiaphysovenine And Carbamate Analogues: A New Class Of Potent Inhibitors Of Cholinesterases.”Med. Chem. Res. 2:229-237 (1992).
Hentze et al., “Molecular control of vertebrate iron metabolism: mRNA-based regulatory circuits operated by iron, nitric oxide, and oxidative stress.”Proc. Natl. Acad. Sci. USA. 93:8175-8182 (Aug. 1996).
Hung et al., “Selective ectodomain phosphorylation and regulated cleavage of β-amyloid precursor protein.”EMBO J. 13(3):534-542 (1994).
Hussaain et al., “Identification of a Novel Aspartic Protease (Asp 2) as β- Secretase.”Mol. Cell Neurosci. 14:419-427 (1999).
Jacobsen et al., “The Release of Alzheimer's Disease β Amyloid Peptide Is Reduced by Phorbol Treatment.”J. Biol. Chem. 269(11):8376-8382 (Mar. 18, 1994).
Julian et al., “Studies in the Indole Series. IV. The Synthesis ofd,l-Eserethole.”J. Am. Chem. Soc. 57:563-566 (Mar. 1935).
Kim et al., “Identification of a Conserved and Functional Iron-responsive Element in the 5′-Untranslated Region of Mammalian Mitochondrial Aconitase.”J. Biol.l Chem. 271(39):24226-24230 (Sep. 27, 1996).
Koike et al., “Thimet Oligopeptidase Cleaves the Full-Length Alzheimer Amyloid Precursor Protein at a β-Secretase Cleavage Site in COS Cell.”J. Biochem. 126:235-242 (1999).
Lahiri et al., “Effects of Cholinesterase Inhibitors on the Secretion of Beta-Amyloid Precursor Protein in Cell Cultures.”Ann. NY Acad. Sci. 26(826):416-421 (1997).
Lahiri et al., “Cholinesterase inhibitors, β-amyloid precursor protein and amyloid β-peptidases in Alzheimers disease.”Acta Neurol. Scand. Suppl. 176:60-67 (2000).
Lahiri et al., “The secretion of amyloid β-peptides is inhibited in tacrine-treated human neuroblastoma cell.”Mol. Brain Res. 62:131-140 (1998).
LeBlanc et al., “Protein Kinase C Activation Increases Release of Secreted Amyloid Precursor Protein without Decrease Aβ Production in Human Primary Neuron Cultures.”J. Neurosci. 18(8):2907-2913 (Apr. 15, 1998).
Lee Wong, “High-performance liquid chromatographic enantiosepartion of intermediates relating to the total synthesis of (-)-physostigmine.”J. Chromat. 523:317-320 (1990).
Lee et al., “Asymmetric Alkylation of Oxindoles: An Approach to the Total Synthesis of (-)-Physostigmine.”J. Org. Chem. 56:872-875 (1991).
Leli et al., “Distinct Mechanism of Differentiation of SH-SY5Y Neurob
Brossi Arnold
Davidson Diane
Giordano Anthony
Greig Nigel H.
Holloway Harold W.
Lambkin Deborah C.
Needle & Rosenberg P.C.
The National Institutes of Health and Axonyx, Inc.
The United States of America as represented by the Department of
LandOfFree
Agents useful for reducing amyloid precursor protein and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Agents useful for reducing amyloid precursor protein and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Agents useful for reducing amyloid precursor protein and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3709354